{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:49:10Z","timestamp":1770976150566,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s40265-013-0058-7","type":"journal-article","created":{"date-parts":[[2013,5,15]],"date-time":"2013-05-15T13:21:44Z","timestamp":1368624104000},"page":"741-753","source":"Crossref","is-referenced-by-count":24,"title":["Inhaled Glycopyrronium Bromide: A Review of its Use in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease"],"prefix":"10.1007","volume":"73","author":[{"given":"Natalie J.","family":"Carter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,16]]},"reference":[{"key":"58_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2011. http:\/\/www.goldcopd.org\/uploads\/users\/files\/GOLD_Report_2011_Feb21.pdf . Accessed 8 Apr 2013."},{"issue":"9","key":"58_CR2","first-page":"374","volume":"46","author":"TR Hudd","year":"2011","unstructured":"Hudd TR, Zaiken K. Management of chronic obstructive pulmonary disease: an emphasis on recently approved medications and products in the pipeline. Formulary. 2011;46(9):374\u201393.","journal-title":"Formulary"},{"key":"58_CR3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1741-7015-9-7","volume":"9","author":"K Atsou","year":"2011","unstructured":"Atsou K, Chouaid C, Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med. 2011;9:7.","journal-title":"BMC Med"},{"key":"58_CR4","unstructured":"World Health Organization. World health statistics. 2008. http:\/\/www.who.int\/whosis\/whostat\/EN_WHS08_Full.pdf . Accessed 8 Apr 2013."},{"key":"58_CR5","unstructured":"Novartis Europharm Ltd. Seebri\u00ae Breezhaler\u00ae (glycopyrronium bromide) powder for inhalation: EU summary of product characteristics. 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002430\/WC500133769.pdf . Accessed 8 Apr 2013."},{"issue":"15","key":"58_CR6","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.2165\/11209700-000000000-00000","volume":"72","author":"JE Frampton","year":"2012","unstructured":"Frampton JE. Aclidinium: in chronic obstructive pulmonary disease. Drugs. 2012;72(15):1999\u20132011.","journal-title":"Drugs"},{"key":"58_CR7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/thx.2007.086041","volume":"63","author":"J Bourbeau","year":"2008","unstructured":"Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63:831\u20138.","journal-title":"Thorax"},{"key":"58_CR8","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000324453","volume":"82","author":"T Agh","year":"2011","unstructured":"Agh T, Inotai A, Meszaros A. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration. 2011;82:328\u201334.","journal-title":"Respiration"},{"issue":"10","key":"58_CR9","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1185\/03007995.2010.516284","volume":"26","author":"M St Charles","year":"2010","unstructured":"St Charles M, Blanchette CM, Silver H, et al. Adherence to controller therapy for chronic obstructive pulmonary disease: a review. Curr Med Res Opin. 2010;26(10):2421\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"96","key":"58_CR10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1183\/09059180.05.00009604","volume":"14","author":"CS Rand","year":"2005","unstructured":"Rand CS. Patient adherence with COPD therapy. Eur Respir Rev. 2005;14(96):97\u2013101.","journal-title":"Eur Respir Rev"},{"issue":"3","key":"58_CR11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/COPD.S3036","volume":"3","author":"RD Restrepo","year":"2008","unstructured":"Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(3):371\u201384.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"58_CR12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.amjopharm.2012.04.002","volume":"10","author":"L Simoni-Wastila","year":"2012","unstructured":"Simoni-Wastila L, Wei Y-J, Qian J, et al. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population. Am J Geriatr Pharmacother. 2012;10(3):201\u201310.","journal-title":"Am J Geriatr Pharmacother"},{"key":"58_CR13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.rmed.2010.09.006","volume":"105","author":"EL Toy","year":"2011","unstructured":"Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105:435\u201341.","journal-title":"Respir Med"},{"key":"58_CR14","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.rmed.2007.05.001","volume":"101","author":"G Tamura","year":"2007","unstructured":"Tamura G, Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med. 2007;101:1895\u2013902.","journal-title":"Respir Med"},{"issue":"3","key":"58_CR15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1183\/09031936.00013109","volume":"34","author":"M Cazzola","year":"2009","unstructured":"Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J. 2009;34(3):757\u201369.","journal-title":"Eur Respir J"},{"key":"58_CR16","unstructured":"Novartis Europharm Ltd. Oslif\u00ae Breezhaler\u00ae (indacaterol) powder for inhalation: EU summary of product characteristics. 2010. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001210\/WC500053307.pdf . Accessed 8 Apr 2013."},{"key":"58_CR17","unstructured":"Boehringer Ingelheim Ltd. Spiriva\u00ae (tiotropium bromide monohydrate) powder for inhalation: UK summary of product characteristics. 2012. http:\/\/www.medicines.org.uk\/EMC\/medicine\/10039\/SPC\/Spiriva+18+microgram+inhalation+powder%2c+hard+capsule\/ . Accessed 8 Apr 2013."},{"key":"58_CR18","unstructured":"Boehringer Ingelheim Ltd. Spiriva\u00ae Respimat\u00ae (tiotropium bromide monohydrate) solution for inhalation: UK summary of product characteristics. 2012. http:\/\/www.medicines.org.uk\/EMC\/medicine\/20134\/SPC\/Spiriva+Respimat+2.5+micrograms+solution+for+inhalation\/ . Accessed 8 Apr 2013."},{"key":"58_CR19","unstructured":"AstraZeneca UK Ltd. Oxis\u00ae Turbohaler\u00ae 6 (formoterol fumarate dihydrate) powder for inhalation: UK summary of product characteristics. 2010. http:\/\/www.medicines.org.uk\/EMC\/medicine\/189\/SPC\/Oxis+Turbohaler+6%2c+inhalation+powder\/ . Accessed 8 Apr 2013."},{"key":"58_CR20","unstructured":"AstraZeneca UK Ltd. Oxis\u00ae Turbohaler\u00ae 12 (formoterol fumarate dihydrate) powder for inhalation: UK summary of product characteristics. 2010. http:\/\/www.medicines.org.uk\/EMC\/medicine\/190\/SPC\/Oxis+Turbohaler+12%2c+inhalation+powder\/ . Accessed 8 Apr 2013."},{"issue":"2","key":"58_CR21","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/jpet.112.194456","volume":"343","author":"DA Sykes","year":"2012","unstructured":"Sykes DA, Dowling MR, Leighton-Davies J, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther. 2012;343(2):520\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"58_CR22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.bjp.0702573","volume":"127","author":"E-B Haddad","year":"1999","unstructured":"Haddad E-B, Patel H, Keeling JE. Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br J Pharmacol. 1999;127:413\u201320.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"58_CR23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bjp.0706724","volume":"148","author":"G Villetti","year":"2006","unstructured":"Villetti G, Bergamaschi M, Bassani F, et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways. Br J Pharmacol. 2006;148(3):291\u20138.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"58_CR24","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1124\/jpet.109.152470","volume":"330","author":"P Casarosa","year":"2009","unstructured":"Casarosa P, Bouyssou T, Germeyer S, et al. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther. 2009;330(2):660\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"58_CR25","unstructured":"European Medicines Agency. Seebri\u00ae Breezhaler\u00ae (glycopyrronium bromide): European Medicines Agency assessment report. 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002430\/WC500133771.pdf . Accessed 8 Apr 2013."},{"key":"58_CR26","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2147\/COPD.S35990","volume":"7","author":"CS Ulrik","year":"2012","unstructured":"Ulrik CS. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int J Chron Obstruct Pulmon Dis. 2012;7:673\u20138.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"58_CR27","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2147\/COPD.S36001","volume":"7","author":"R Buhl","year":"2012","unstructured":"Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:729\u201341.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"10","key":"58_CR28","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.rmed.2010.04.006","volume":"104","author":"C Verkindre","year":"2010","unstructured":"Verkindre C, Fukuchi Y, Fl\u00e9male A, et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2010;104(10):1482\u20139.","journal-title":"Respir Med"},{"issue":"2","key":"58_CR29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5414\/CP201612","volume":"50","author":"R Sechaud","year":"2012","unstructured":"Sechaud R, Renard D, Zhang-Auberson L, et al. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). Int J Clin Pharmacol Ther. 2012;50(2):118\u201328.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"58_CR30","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1465-9921-12-156","volume":"12","author":"A D\u2019Urzo","year":"2011","unstructured":"D\u2019Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011;12:156.","journal-title":"Respir Res"},{"issue":"5","key":"58_CR31","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1183\/09031936.00040712","volume":"40","author":"E Kerwin","year":"2012","unstructured":"Kerwin E, H\u00e9bert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106\u201314.","journal-title":"Eur Respir J"},{"key":"58_CR32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/COPD.S32451","volume":"7","author":"KM Beeh","year":"2012","unstructured":"Beeh KM, Singh D, Di Scala L, et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503\u201313.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"58_CR33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.rmed.2010.10.021","volume":"105","author":"C Fogarty","year":"2011","unstructured":"Fogarty C, Hattersley H, Di Scala L, et al. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2011;105(3):337\u201342.","journal-title":"Respir Med"},{"key":"58_CR34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1471-2466-12-74","volume":"12","author":"H Arievich","year":"2012","unstructured":"Arievich H, Overend T, Renard D, et al. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm Med. 2012;12:74.","journal-title":"BMC Pulm Med"},{"issue":"5","key":"58_CR35","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.pupt.2010.04.005","volume":"23","author":"C Vogelmeier","year":"2010","unstructured":"Vogelmeier C, Verkindre C, Cheung D, et al. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther. 2010;23(5):438\u201344.","journal-title":"Pulm Pharmacol Ther"},{"key":"58_CR36","unstructured":"Novartis Pharmaceuticals Canada Inc. Seebri\u00ae Breezhaler\u00ae (glycopyrronium bromide) powder for inhalation: Canadian prescribing information. 2012."},{"key":"58_CR37","unstructured":"Novartis. Novartis receives European Commission approval for once-daily Seebri\u00ae Breezhaler\u00ae as maintenance COPD treatment in the EU. 2012. http:\/\/www.novartis.com\/newsroom\/media-releases\/en\/2012\/1645116.shtml . Accessed 8 Apr 2013."},{"key":"58_CR38","unstructured":"Novartis. Novartis QVA149 phase III study meets primary endpoint in reducing exacerbations in COPD patients, filing in EU and Japan by end of year. 2012. http:\/\/www.novartis.com\/newsroom\/media-releases\/en\/2012\/1637183.shtml . Accessed 8 Apr 2013."},{"key":"58_CR39","unstructured":"Novartis. Novartis data at ERS shows efficacy of once-daily COPD portfolio versus comparators, further establishes dual-bronchodilator QVA149. 2012. http:\/\/www.novartis.com\/newsroom\/media-releases\/en\/2012\/1638207.shtml . Accessed 8 Apr 2013."},{"key":"58_CR40","unstructured":"Novartis. Novartis QVA149 phase III COPD studies meet primary endpoints. 2012. http:\/\/www.novartis.com\/newsroom\/media-releases\/en\/2012\/1599186.shtml . Accessed 8 Apr 2013."},{"key":"58_CR41","unstructured":"The Pharma Letter. Novartis\/Vectura\u2019s QVA149 is filed as a treatment for COPD in Europe. 2012. http:\/\/www.thepharmaletter.com\/file\/117552\/novartisvecturas-qva149-is-filed-as-a-treatment-for-copd-in-europe-certican-eu-approval.html . Accessed 8 Apr 2013."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0058-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0058-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0058-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:41:31Z","timestamp":1559504491000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0058-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["58"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0058-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}